news
FDA grants expanded approval for hepatitis drug
The FDA’s authorisation helps to address the “significant” remaining need for acute hepatitis C treatments, according to AbbVie.
List view / Grid view
Hepatitis C (HCV)
news
Can Hepatitis C drugs reduce symptoms of PTSD?
Direct acting antivirals used to treat hepatitis C virus infection may improve symptoms of posttraumatic stress disorder (PTSD) in patients without the disease, according to new research.
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-300x278.jpg)
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-e1652444508201.jpg)
news
Roche announces plans to improve diagnosis and treatments in developing countries
Roche shares initiative commitments that will extend prophylactic treatment access to patients with haemophilia, as well as investments to provide testing capabilities for HIV and Tuberculosis in developing countries.
news
EMA’s human medicine committee (CHMP) meeting highlights, July 2021
The Committee for Medicinal Products for Human Use (CHMP) recommended two medicines for approval and provided a negative opinion on Nouryant.
news
Successful kidney transplants from hepatitis C infected individuals
Transplantation followed by antiviral therapy cured hepatitis C in 100 percent of patients receiving kidneys from infected donors...
news
Sofosbuvir found to be effective against Zika virus
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus...
news
FDA approves AbbVie’s Mavyret for hepatitis C
The FDA has approved Mavyret to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis...
news
BIOCAD does its sums for growth
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
news
Costs for generic hepatitis C drugs in India paid back in 5 years
7 June 2017 | By Niamh Marriott, Junior Editor
Treatment with generic directly-acting antiviral drugs available in India increases lifespan while reducing lifetime health care costs
news
Gilead’s Phase II study showed 99% HCV cure rates
26 April 2017 | By Niamh Marriott, Junior Editor
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
news
AbbVie’s HCV/ compensated cirrhosis drug achieved 99% SVR12 rate
24 April 2017 | By Niamh Marriott, Junior Editor
AbbVie announced that 99% (145/146) of chronic hepatitis C virus (HCV) infected patients with genotype and compensated cirrhosis (Child-Pugh A)...
news
AbbVie receives CHMP positive opinion for Hep C tablet combination
2 March 2017 | By Niamh Marriott, Digital Editor
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…
article
H is for Hepatitis C
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
H is for Hepatitis C - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in Hep C research...
news
AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load...
news
FDA approves Roche’s blood screening assay for donor screening
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
